...
首页> 外文期刊>European thyroid journal >A Placebo-Controlled, Blinded and Randomised Study on the Effects of Recombinant Human Thyrotropin on Quality of Life in the Treatment of Thyroid Cancer
【24h】

A Placebo-Controlled, Blinded and Randomised Study on the Effects of Recombinant Human Thyrotropin on Quality of Life in the Treatment of Thyroid Cancer

机译:甲状腺激素治疗中重组人甲状腺素对生活质量影响的安慰剂对照,盲法和随机研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: It is well known that thyroid hormone withdrawal (THW) in thyroid cancer patients can induce a decrease in quality of life (QOL). Recombinant human thyrotropin (rh-TSH) has been used to avoid this; however, no blinded studies have ever documented the effect. Objective: To compare QOL in patients with differentiated thyroid cancer (DTC) treated with either rh-TSH or liothyronine (L-T_3) THW for 10 days. Study Design: Double-blind, randomised crossover. Patients: Fifty-six patients with DTC treated by total thyroidectomy and indication for postsurgery radioiodine (Rl) ablation therapy. Intervention: Randomisation to either L-T_3 and rh-TSH prior to the first Rl course and following this to ingest placebo tablets and receive placebo injections before a second Rl uptake measurement 4-6 months later, or to receive placebo before the primary Rl ablation and active therapy 4-6 months later. Main Outcome Measures: QOL was measured by SF-36 and 2 visual analogue scale (VAS) scores at baseline and during Rl therapy or Rl uptake.
机译:背景:众所周知,甲状腺癌患者的甲状腺激素戒断(THW)会导致生活质量(QOL)下降。重组人促甲状腺激素(rh-TSH)已被用来避免这种情况。但是,还没有盲目的研究证明这种作用。目的:比较rh-TSH或碘甲状腺素(L-T_3)THW治疗10天的分化型甲状腺癌(DTC)患者的生活质量。研究设计:双盲,随机交叉。患者:通过全甲状腺切除术治疗的56例DTC患者以及手术后放射性碘(R1)消融治疗的指征。干预:在第一个R1疗程之前随机分配至L-T_3和rh-TSH,然后在4-6个月后的第二次R1摄取测量之前摄入安慰剂片剂并接受安慰剂注射,或者在主要R1消融之前接受安慰剂并在4-6个月后进行积极治疗。主要结果测量:在基线以及在R1治疗或R1摄取过程中,通过SF-36和2个视觉模拟量表(VAS)评分测量QOL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号